United Therapeutics Stock Performance
| UTHR Stock | USD 318.89 38.61 10.80% |
The entity has a beta of 0.21, which indicates not very significant fluctuations relative to the market. As returns on the market increase, United Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding United Therapeutics is expected to be smaller as well. At this point, United Therapeutics has a negative expected return of -0.23%. Please make sure to validate United Therapeutics' jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if United Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days United Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's technical indicators remain relatively invariable which may send shares a bit higher in March 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return (10.80) | Five Day Return (13.01) | Year To Date Return (11.47) | Ten Year Return 105.67 | All Time Return 5.1 K |
Last Split Factor 2:1 | Last Split Date 2009-09-23 |
1 | Disposition of 402 shares by Michael Benkowitz of United Therapeutics at 374.3507 subject to Rule 16b-3 | 12/06/2024 |
2 | Disposition of 15000 shares by Sullivan Louis W of United Therapeutics at 175.43 subject to Rule 16b-3 | 12/18/2024 |
3 | Disposition of 1851 shares by Sullivan Louis W of United Therapeutics subject to Rule 16b-3 | 12/19/2024 |
4 | Disposition of 2500 shares by Michael Benkowitz of United Therapeutics at 111.0 subject to Rule 16b-3 | 12/26/2024 |
5 | Disposition of 7700 shares by Mahon Paul A of United Therapeutics at 163.3 subject to Rule 16b-3 | 01/02/2025 |
6 | Disposition of 600 shares by Michael Benkowitz of United Therapeutics at 367.8917 subject to Rule 16b-3 | 01/13/2025 |
7 | Burney Co. Increases Holdings in United Therapeutics Co. | 01/15/2025 |
8 | Disposition of 100 shares by Michael Benkowitz of United Therapeutics at 375.22 subject to Rule 16b-3 | 01/27/2025 |
9 | KBC Group NV Purchases 7,169 Shares of United Therapeutics Co. - MarketBeat | 01/28/2025 |
10 | Disposition of 1142 shares by Michael Benkowitz of United Therapeutics at 345.6904 subject to Rule 16b-3 | 02/11/2025 |
11 | TFB Advisors LLC Trims Stock Position in United Therapeutics Co. | 02/12/2025 |
12 | Strength Seen in United Therapeutics Can Its 4.9 percent Jump Turn into More Strength | 02/13/2025 |
13 | United Therapeutics Buy, Sell, or Hold Post Q3 Earnings | 02/14/2025 |
14 | Disposition of 400 shares by Michael Benkowitz of United Therapeutics at 373.6725 subject to Rule 16b-3 | 02/18/2025 |
15 | United Therapeutics Corp to Announce Q4 and Full Year 2024 Financial Results | 02/20/2025 |
16 | Disposition of 200 shares by Michael Benkowitz of United Therapeutics at 363.48 subject to Rule 16b-3 | 02/24/2025 |
17 | United Therapeutics Shares Drop After Disappointing Earnings | 02/26/2025 |
| Begin Period Cash Flow | 1.2 B |
United |
United Therapeutics Relative Risk vs. Return Landscape
If you would invest 37,049 in United Therapeutics on November 29, 2024 and sell it today you would lose (5,160) from holding United Therapeutics or give up 13.93% of portfolio value over 90 days. United Therapeutics is currently does not generate positive expected returns and assumes 2.2125% risk (volatility on return distribution) over the 90 days horizon. In different words, 19% of stocks are less volatile than United, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
United Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for United Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as United Therapeutics, and traders can use it to determine the average amount a United Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1035
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | UTHR |
Estimated Market Risk
| 2.21 actual daily | 19 81% of assets are more volatile |
Expected Return
| -0.23 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average United Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of United Therapeutics by adding United Therapeutics to a well-diversified portfolio.
United Therapeutics Fundamentals Growth
United Stock prices reflect investors' perceptions of the future prospects and financial health of United Therapeutics, and United Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on United Stock performance.
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.40 % | ||||
| Operating Margin | 0.55 % | ||||
| Current Valuation | 13.03 B | ||||
| Shares Outstanding | 44.64 M | ||||
| Price To Earning | 23.49 X | ||||
| Price To Book | 2.62 X | ||||
| Price To Sales | 5.79 X | ||||
| Revenue | 2.88 B | ||||
| Gross Profit | 2.45 B | ||||
| EBITDA | 1.38 B | ||||
| Net Income | 1.2 B | ||||
| Cash And Equivalents | 2.26 B | ||||
| Cash Per Share | 49.55 X | ||||
| Total Debt | 920 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 8.10 X | ||||
| Book Value Per Share | 136.74 X | ||||
| Cash Flow From Operations | 1.33 B | ||||
| Earnings Per Share | 20.31 X | ||||
| Market Capitalization | 15.96 B | ||||
| Total Asset | 7.36 B | ||||
| Retained Earnings | 7.22 B | ||||
| Working Capital | 2.75 B | ||||
| Current Asset | 1.28 B | ||||
| Current Liabilities | 440.82 M | ||||
About United Therapeutics Performance
Assessing United Therapeutics' fundamental ratios provides investors with valuable insights into United Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the United Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 186.09 | 331.89 | |
| Return On Tangible Assets | 0.16 | 0.17 | |
| Return On Capital Employed | 0.21 | 0.22 | |
| Return On Assets | 0.16 | 0.17 | |
| Return On Equity | 0.19 | 0.19 |
Things to note about United Therapeutics performance evaluation
Checking the ongoing alerts about United Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for United Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| United Therapeutics generated a negative expected return over the last 90 days | |
| United Therapeutics is unlikely to experience financial distress in the next 2 years | |
| Over 98.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from gurufocus.com: United Therapeutics Shares Drop After Disappointing Earnings |
- Analyzing United Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether United Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining United Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating United Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of United Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of United Therapeutics' stock. These opinions can provide insight into United Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.